1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases

Neuroscience Letters

Volumn 382, Issue 3, 2005, Pages 327-331

  Ucar, Gulberk ^a   Gokhan, Nesrin ^a   Yesilada, Akgul ^a   Bilgin, A Altan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acetylcholinesterase; Butrylcholinesterase; Inhibition; N Substituted pyrazoline derivatives

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; MONOAMINE OXIDASE B INHIBITOR; PARGYLINE; PHENOTHIAZINE; PROFENAMINE; PYRAZOLINE DERIVATIVE; RIVASTIGMINE; SELEGILINE;

ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; PARKINSON DISEASE; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ERYTHROCYTES; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PLASMA; PYRAZOLES; SUBSTRATE SPECIFICITY; THIOCARBAMATES;

EID: 19544390899     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.03.028     Document Type: Article

References (21)

1. E. Amaiz, V. Jelic, O. Almkvist, L.O. Wahlund, B. Winblad, S. Valind, and A. Nordberg Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairement Neuroreport 26 2001 851 855
2. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data bank Nucleic Acids Res. 28 2000 235 242
3. M.M. Bradford A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
4. +)-ATPase activities, antioxidant status and learning performance of aged rats Pharmacol. Res. 48 2003 245 251
5. I. Ceballos-Picot, J.V. Trivier, A. Nicole, P.M. Sinet, and M. Thevenin Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes Clin. Chem. 38 1992 66 70
6. J.T. Coyle, D.L. Price, and M.R. DeLong Alzheimer's disease: a disorder of cortical cholinergic innervation Science 44 1983 1184 1190
7. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
8. B. Filip, and E. Kolibas Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group J. Psychiatry Neurosci. 24 1999 234 243
9. E. Giacobin Selective inhibitors of butyrylcholinesterase: a valid alternative for theraphy of Alzheimer's disease? Drugs Aging 18 2001 891 898
10. N. Gökhan, A. Yesilada, G. Ucar, K. Erol, and A. Bilgin 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors Arch. Pharm. Med. Chem. 336 2003 362 371
11. M. Harel, I. Schalk, L.E. Sabatier, F. Bouet, M. Goeldner, C. Hirth, P.H. Axelsen, I. Silman, and J.L. Sussman Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase Proc. Natl. Acad. Sci. U.S.A. 90 1993 9031 9035
12. L.S. Honig, and R. Mayeux Natural history of Alzheimer's disease Aging (Milano) 13 2001 171 182
13. G. Kryger, M. Harel, K. Giles, L. Toker, B. Velan, A. Lazar, C. Kronman, D. Barak, N. Ariel, A. Shafferman, I. Silman, and J.L. Sussman Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II Acta Crystallogr. Sect. D 56 2000 1385 1394
14. W. Maruyama, M. Weinstock, M.B.H. Youdim, M. Nagai, and M. Naoi Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)- aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase monoamine oxidase inhibitor Neurosci. Lett. 341 2003 33 236
15. J. Massoulié, L. Pezzementi, S. Bom, and E. Krejci Molecular and cellular biology of cholinesterases Prog. Neurobiol. 41 1993 31 41
16. C.B. Millard, and C.A. Broomfield Anticholinesterases: medical applications of neurochemical principles J. Neurochem. 64 1995 1909 1918
17. Y. Nicolet, O. Lockridge, P. Masson, J.C. Fontecilla-Camps, and F. Nachon Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products J. Biol. Chem. 278 2003 41141 41147
18. P. Rieder, W. Danielczyk, and E. Grünblatt Monoamine oxidase-B inhibition in Alzheimer's disease Neurotoxicology 25 2004 271 277
19. A. Saxena, A.M. Redman, X. Jiang, O. Lockridge, and B.P. Doctor Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase Biochemistry 36 1997 14642 14651
20. W. Slikker, M.B. Youdim, G.C. Palmer, E. Hall, C. Williams, and B. Trembly The future of neuroprotection Ann. N. Y. Acad. Sci. 890 1999 529 533
21. M.B.H. Youdim, and M. Weinstock Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline Mech. Ageing. Dev. 123 2002 1081 1086